Panacea Biotec is currently trading at Rs. 160.80, up by 6.85 points or 4.45 % from its previous closing of Rs. 153.95 on the BSE.
The scrip opened at Rs. 155.90 and has touched a high and low of Rs. 167.80 and Rs. 153.05 respectively. So far 42035 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 178.30 on 27-Jan-2017 and a 52 week low of Rs. 85.50 on 26-May-2016.
Last one week high and low of the scrip stood at Rs. 167.80 and Rs. 151.30 respectively. The current market cap of the company is Rs. 987.06 crore.
The promoters holding in the company stood at 74.60%, while Institutions and Non-Institutions held 0.06% and 25.34% respectively.
Panacea Biotec has launched world's first fully liquid whole cell Pertussis (wP) based hexavalent combination vaccine, EasySix, a vaccine Researched, Developed and Manufactured by Panacea Biotec in India. EasySix is indicated for primary immunization to protect newborn babies against six common preventable diseases that is Diphtheria, Tetanus, Whooping Cough, Meningitis (due to H. Influenza type b), Hepatitis B and Polio.
EasySix is a fully liquid ready-to-use hexavalent vaccine made using high quality antigens complying to WHO's cGMP requirements. The fully liquid 6-in-1 combination vaccine EasySix requires no reconstitution, therefore saves time, is convenient and minimizes chances of error.
Panacea Biotec is one of India’s leading research based Biopharmaceutical Company with established research, manufacturing and marketing capabilities. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.